Resmed Aktie 1058638 / AU000000RMD6
22.80
EUR
0.20
EUR
0.88%
22.11.2024
STU
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Resmed Dividenden Kalender
Datum | Name | Rendite * | Dividende | Währung |
---|---|---|---|---|
2024 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 1.02 | 0.30 | AUD |
2023 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.67 | 0.22 | AUD |
2022 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.54 | 0.17 | AUD |
2021 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.45 | 0.15 | AUD |
2020 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.65 | 0.18 | AUD |
2019 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.84 | 0.14 | AUD |
2018 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.90 | 0.13 | AUD |
2017 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 1.61 | 0.16 | AUD |
2016 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 1.47 | 0.12 | AUD |
2015 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 1.57 | 0.11 | AUD |
Gewinn je Aktie- Resmed
0.3 18 | 0.4 19 | 0.6 20 | 0.4 21 | 0.7 22 | 0.9 23 | 1.1 24 |
Umsatz je Aktie- Resmed
2.1 18 | 2.5 19 | 3.0 20 | 2.9 21 | 3.4 22 | 4.3 23 | 4.8 24 |
KGV- Resmed
49.8 18 | 43.8 19 | 43.3 20 | 75.4 21 | 42.0 22 | 36.2 23 | 27.6 24 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: Die Aktie (in AUD)
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Gewinn je Aktie berichtet | 0.28 | 0.39 | 0.64 | 0.43 | 0.73 | 0.91 | 1.06 |
Gewinn je Aktie unverwässert | 0.29 | 0.40 | 0.64 | 0.44 | 0.74 | 0.91 | 1.06 |
Gewinn je Aktie verwässert | 0.28 | 0.39 | 0.64 | 0.43 | 0.73 | 0.91 | 1.06 |
Dividende pro Aktie | 0.13 | 0.14 | 0.18 | 0.15 | 0.17 | 0.22 | 0.30 |
Gesamtdividendenausschüttung in Mio. | 257.47 | 296.04 | 335.77 | 303.93 | 338.31 | 383.97 | 430.83 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: Unternehmenskennzahlen (in AUD)
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Umsatz je Aktie | 2.10 | 2.52 | 3.03 | 2.93 | 3.36 | 4.26 | 4.85 |
KGV (Jahresendkurs, EPS unverwässert) | 49.84 | 43.85 | 43.25 | 75.41 | 41.99 | 36.24 | 27.56 |
KGV (Jahresendkurs, EPS verwässert) | 49.84 | 43.85 | 43.25 | 75.41 | 41.99 | 36.26 | 27.56 |
KGV (Jahresendkurs) | 49.84 | 43.85 | 43.25 | 75.41 | 41.99 | 36.24 | 27.56 |
Dividendenrendite Jahresende in % | 0.90 | 0.84 | 0.65 | 0.45 | 0.54 | 0.67 | 1.02 |
Eigenkapitalquote in % | 67.20 | 50.45 | 54.43 | 61.03 | 65.95 | 61.17 | 70.78 |
Fremdkapitalquote in % | 32.80 | 49.55 | 45.57 | 38.97 | 34.05 | 38.83 | 29.22 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: GuV (in Mio. AUD)
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Umsatzerlöse | 3’020.23 | 3’644.78 | 4’411.00 | 4’285.61 | 4’934.05 | 6’278.17 | 7’149.98 |
Umsatzveränderung in % | 10.21 | 20.68 | 21.02 | -2.84 | 15.13 | 27.24 | 13.89 |
Bruttoergebnis vom Umsatz | 1’698.13 | 2’043.83 | 2’517.55 | 2’423.80 | 2’748.56 | 3’439.61 | 3’981.12 |
Bruttoergebnisveränderung in % | 10.86 | 20.36 | 23.18 | -3.72 | 13.40 | 25.14 | 15.74 |
Operatives Ergebnis | 723.07 | 889.30 | 1’206.88 | 1’223.08 | 1’379.34 | 1’712.63 | 2’112.23 |
Veränderung Operatives Ergebnis in % | 19.39 | 22.99 | 35.71 | 1.34 | 12.78 | 24.16 | 23.33 |
Ergebnis vor Steuern | 672.80 | 725.51 | 1’093.55 | 1’184.62 | 1’324.46 | 1’637.80 | 1’930.14 |
Veränderung Ergebnis vor Steuern in % | 21.17 | 7.83 | 50.73 | 8.33 | 11.80 | 23.66 | 17.85 |
Ergebnis nach Steuer | 407.29 | 565.74 | 927.36 | 636.11 | 1’074.80 | 1’334.36 | 1’558.02 |
Veränderung Ergebnis nach Steuer in % | -10.26 | 38.90 | 63.92 | -31.41 | 68.96 | 24.15 | 16.76 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: Bilanz (in Mio. AUD)
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Gesamtverbindlichkeiten | 1’360 | 2’901 | 3’036 | 2’454 | 2’523 | 3’939 | 3’007 |
Langzeit Gesamtverbindlichk. pro Aktie | 0.47 | 1.47 | 1.49 | - | 1.04 | 1.90 | 1.12 |
Eigenkapital | 2’787 | 2’953 | 3’627 | 3’844 | 4’887 | 6’204 | 7’283 |
Veränderung Eigenkapital in % | 9.04 | 5.96 | 22.82 | 5.98 | 27.15 | 26.95 | 17.39 |
Bilanzsumme | 4’147 | 5’853 | 6’663 | 6’298 | 7’411 | 10’143 | 10’290 |
Veränderung Bilanzsumme in % | -8.29 | 41.15 | 13.83 | -5.48 | 17.67 | 36.87 | 1.45 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: Sonstige Angaben (in AUD)
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Gewinn je Aktie (unverwässert) | 0.29 | 0.40 | 0.64 | 0.44 | 0.74 | 0.91 | 1.06 |
Veränderung Gewinn je Aktie (unverwässert) in % | -11.09 | 38.56 | 62.53 | -31.86 | 68.07 | 23.57 | 16.55 |
Gewinn je Aktie (verwässert) | 0.28 | 0.39 | 0.64 | 0.43 | 0.73 | 0.91 | 1.06 |
Veränderung Gewinn je Aktie (verwässert) in % | -11.09 | 38.42 | 62.59 | -31.77 | 68.26 | 23.81 | 16.69 |
Anzahl Mitarbeiter | 5’940 | 7’240 | 7’770 | 7’970 | 8’160 | 10’140 | 9’980 |
Veränderung Anzahl Mitarbeiter in % | -2.30 | 21.89 | 7.32 | 2.57 | 2.38 | 24.26 | -1.58 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh Termine
Unternehmen | Event | Datum |
---|---|---|
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | Quartalszahlen | 23.01.2025 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | Quartalszahlen | 24.04.2025 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | Quartalszahlen | 31.07.2025 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | Quartalszahlen | 23.10.2025 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh vergangene Termine
Terminart | Info | Datum |
---|---|---|
Hauptversammlung | Annual General Meeting | 21.11.2024 |
Quartalszahlen | Q1 2025 Earnings Release | 24.10.2024 |
Quartalszahlen | Q4 2024 Earnings Release | 01.08.2024 |
Quartalszahlen | Q3 2024 Earnings Release | 25.04.2024 |
Quartalszahlen | Q2 2024 Earnings Release | 24.01.2024 |
Hauptversammlung | Annual General Meeting | 16.11.2023 |
Quartalszahlen | Q1 2024 Earnings Release | 26.10.2023 |
Quartalszahlen | Q4 2023 Earnings Release | 03.08.2023 |
Quartalszahlen | Q3 2023 Earnings Release | 27.04.2023 |
Quartalszahlen | Q2 2023 Earnings Release | 26.01.2023 |
Hauptversammlung | Annual General Meeting | 17.11.2022 |
Quartalszahlen | Q1 2023 Earnings Release | 27.10.2022 |
Quartalszahlen | Q4 2022 Earnings Release | 11.08.2022 |
Quartalszahlen | Q3 2022 Earnings Release | 28.04.2022 |
Quartalszahlen | Q2 2022 Earnings Release | 27.01.2022 |
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 100.00 |
Vanguard Australian Shares Index Fund | 0.61 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 7’770 | 7’970 | 8’160 | 10’140 | 9’980 |
Umsatz pro Mitarbeiter in Mio. EUR | 0.57 | 0.54 | 0.60 | 0.62 | 0.72 |
Bilanz (in Mio. AUD) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 2’213 | 2’098 | 2’809 | 3’557 | 3’530 |
Summe Anlagevermögen | 4’450 | 4’200 | 4’602 | 6’586 | 6’760 |
Summe Aktiva | 6’663 | 6’298 | 7’411 | 10’143 | 10’290 |
Bilanz (in Mio. AUD) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 1’887 | 1’057 | 1’334 | 2’373 | 1’309 |
Summe Fremdkapital | 3’036 | 2’454 | 2’523 | 3’939 | 3’007 |
Summe Eigenkapital | 3’627 | 3’844 | 4’887 | 6’204 | 7’283 |
Summe Passiva | 6’663 | 6’298 | 7’411 | 10’143 | 10’290 |
Adresse
9001 Spectrum Center Boulevard, 92123 San Diego | |
Telefon | +1 (858) 836-5000 |
URL | http://www.resmed.com |
Management
Alastair Robertson
Chief Information Officer |
Amy Wakeham
Chief Investor Relations Officer |
Andrew Price
Chief Supply Chain Officer |
Bobby Ghoshal
Chief Commercial Officer-SaaS |
Brett A. Sandercock
Chief Financial Officer |
Carlos M. Nunez
Chief Medical Officer |
Carol J. Burt
Independent Director |
Christopher J. DelOrefice
Independent Director |
Dawn Haake
Chief Quality Officer |
Desney Tan
Independent Director |
Geoff Neilson
Senior Vice President-Global Supplier Alliance |
Harjit Gill
Independent Director |
Hemanth Reddy
Chief Strategy Officer |
Jan D. de Witte
Independent Director |
Jim Ellis
Chief Compliance Officer |
John B. Hernandez
Independent Director |
Justin G. Leong
Chief Product Officer |
Karen Ruth Drexler
Independent Director |
Lucile Blaise
Senior VP-Strategy & Business Development |
Michael Fliss
Chief Revenue Officer |
Michael J. Farrell
Chairman & Chief Executive Officer |
Michael Rider
Secretary & Chief Legal Officer |
Peter C. Farrell
Chairman-Emeritus |
Richard Sulpizio
Independent Director |
Ronald R. Taylor
Lead Independent Director |
Shane Azzi
Chief Supply Chain Officer |
Todd Friedman
Chief Information Security Officer |
Vered Keisar
Chief People Officer |
Yvonne-Katrin Pucknat
Chief Marketing Officer |